<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Lower rate of progression to clinical type 1 diabetes after teplizumab treatment</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Lower rate of progression to clinical type 1 diabetes after teplizumab treatment</h1>
<div class="graphic"><div class="figure"><div class="ttl">Lower rate of progression to clinical type 1 diabetes after teplizumab treatment</div><div class="cntnt"><img src="data:png;base64,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"/></div><div class="graphic_lgnd">Progression to clinical (stage 3) type 1 diabetes in individuals with preclinical (stage 2) disease who were randomly assigned to treatment with teplizumab or placebo. The number of participants who progressed to clinical type 1 diabetes is shown for the initial trial analysis and after extended follow-up.</div><div class="graphic_footnotes">T1D: type 1 diabetes mellitus.</div><div class="graphic_reference">Data from: Sims EK, Bundy BN, Stier K, et al. Teplizumab improves and stabilizes beta cell function in antibody-positive high-risk individuals. Sci Transl Med 2021; 13:eabc8980.</div><div id="graphicVersion">Graphic 141628 Version 1.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
